Q2 FY2026 · ended Jun 30, 2026 · Revenue $87,970, -50.6% YoY · Filed Aug 14, 2026
BioCorRx Inc. (BICX) files with the SEC under industry code 8093, Services-Specialty Outpatient Facilities, NEC. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $87,970 and a net loss of $964,774. As of Jun 30, 2026 it held $21,237 in cash and investments and $137,869 in total debt.
Revenue
$87,970
-50.6% vs year-ago quarter
Net income
$-964,774
+21.8% vs year-ago quarter
Operating cash flow
$-440,289
+46.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.03
+57.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
29.76M
+2.4% vs prior quarter
Net cash
$-116,632
Q2 FY2026
Operating margin
-775.9%
TTM
Company profile
- Industry
- Services-Specialty Outpatient Facilities, NEC (SIC 8093)
- Listed as
- BICX (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Anaheim, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1443863
- Former names
- FRESH START PRIVATE MANAGEMENT, INC. (until Feb 4, 2014); Cetrone Energy CO (until Nov 15, 2010)
Other Services-Specialty Outpatient Facilities, NEC companies
- Concentra Group Holdings Parent, Inc. CON
- Acadia Healthcare Company, Inc. ACHC
- Elite Health Systems Inc. EHSI
- Aesthetic Medical International Holdings Group Ltd PAIYY
All 5 Services-Specialty Outpatient Facilities, NEC companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $87,970 | $214,539 | -$151,118 | $635,224 | $178,238 |
| Operating income | -$1.5M | -$956,000 | -$534,185 | -$1.9M | -$1.4M |
| Net income | -$964,774 | -$831,227 | $552,555 | -$1.9M | -$1.2M |
| Diluted EPS | -$0.03 | -$0.03 | $0.02 | -$0.11 | -$0.07 |
| Operating cash flow | -$440,289 | -$432,971 | -$847,722 | -$634,447 | -$816,122 |
| Total assets | $1.9M | $2.3M | $2.1M | $7.5M | $6.7M |
| Total liabilities | $14.4M | $13.9M | $13.7M | $20.3M | $19.7M |
| Stockholders' equity | -$12.2M | -$11.5M | -$11.2M | -$13.5M | -$12.6M |
| Cash and investments | $21,237 | $211,911 | $139,360 | $287,688 | $111,872 |
| Total debt | $137,869 | $148,604 | $159,127 | $169,443 | $179,555 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 4, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 2, 2026 | Mar 26, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 499 BioCorRx Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.